Delmas, P D <br/><br/>
Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study.  [electronic resource] 

 -  Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA  Oct 2004 
 - 792-8 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial 
<br/><br/><label>ISSN: </label>0937-941X 
<br/><br/><label>Standard No.: </label>10.1007/s00198-004-1602-9  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Administration, Oral<br/>Aged<br/>Aged, 80 and over<br/>Biomarkers--blood<br/>Bone Density--physiology<br/>Bone Resorption--complications<br/>Collagen--urine<br/>Collagen Type I<br/>Creatinine--urine<br/>Diphosphonates--administration & dosage<br/>Double-Blind Method<br/>Drug Administration Schedule<br/>Female<br/>Hip<br/>Humans<br/>Ibandronic Acid<br/>Lumbar Vertebrae--physiopathology<br/>Middle Aged<br/>Osteocalcin--blood<br/>Peptides--urine<br/>Risk Factors<br/>Spinal Fractures--etiology<br/>Treatment Outcome